{"anticipatedPostingDate":"2027-09","denomUnitsSelected":"Participants","description":"SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 37 days after last dose that were absent before treatment or that worsened relative to pretreatment state.","reportingStatus":"NOT_POSTED","timeFrame":"From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)","title":"Number of Participants With Serious TEAE","type":"SECONDARY"}